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Abstract
Background: The search for an efficacious HIV vaccine is a global priority. To date only one HIV vaccine trial (RV144)
has shown modest efficacy in a phase III trial. With existing different HIV-1 subtypes and frequent mutations, multiple
trials are needed from different geographical sites particularly in sub-Saharan Africa where most HIV infections occur.
Thus, motivations to participate in HIV vaccine trials among Tanzanians need to be assessed. This paper describes the
motives of Police Officers who showed great interest to volunteer in HIVIS-03 in Dar es Salaam, Tanzania.
Methods: A descriptive cross-sectional study was conducted among Police Officers who showed interest to participate
in the HIVIS-03, a phase I/II HIV vaccine trial in Dar es Salaam. Prior to detailed training sessions about HIV vaccine trials,
the potential participants narrated their individual motives to participate in the trial on a piece of paper. Descriptive
analysis using content approach and frequency distributions were performed.
Results: Of the 265 respondents, 242 (91.3 %) provided their socio-demographic characteristics as well as reasons that
would make them take part in the proposed trial. Majority, (39.7 %), cited altruism as the main motive. Women were
more likely to volunteer due to altruism compared to men (P < 0.01). Researchers’ explanations about HIV/AIDS vaccine
studies motivated 15.3 %. More men (19.6 %) than women (1.7 %) were motivated to volunteer due to researchers’
explanations (P < 0.001). Also, compared to other groups, those unmarried and educated up to secondary level of
education were motivated to volunteer due to researchers’ explanation (P < 0.05). Other reasons were: desire to
become a role model (18.6 %); to get knowledge for educating others (14.0 %); to cooperate with researchers in
developing an HIV vaccine (9.5 %); to get protection against HIV infection (7.0 %), and severity of the disease
within families (6.2 %). These results were supported by testimonies from both men and women.
Conclusions: Participation in an HIV vaccine trial in a Tanzanian context is likely to be influenced by altruism and
comprehensive education about the trial. Gender differences, marital status and education level need to be considered
to enhance participation in future HIV vaccine trials.
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Background
For more than three decades HIV/AIDS remains a pub-
lic health concern. To date several HIV vaccine trials
have been conducted to develop an effective preventive
vaccine against HIV transmission [1]. However, only one
HIV vaccine candidate (RV 144) has shown a modest ef-
ficacy in a phase III trial [2]. Due to existing viral
mutations, multiple efficacy trials will be required from
different parts of the world. In line with immunological
studies, several studies have been conducted in various
parts of the world to assess people’s willingness to partici-
pate in HIV vaccine trials [3–10]. A few of such studies
have been conducted in sub-Saharan African countries
[11–14]. Barriers such as fear of safety of an experimental
vaccine, mistrust, and various concerns have been exten-
sively cited among potential HIV vaccine trial participants
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vaccine trials are needed particularly in sub Saharan Africa
where most HIV infections occur.
Corresponding to the global efforts, Tanzania has been
conducting Phase I/II HIV vaccine trials. The first phase
I/II HIV vaccine trial study (HIVIS-03) was conducted
in 2007 among members of the Police force in Dar es
Salaam, Tanzania. Preparatory workshops (sensitization
meetings) were conducted among Police Officers of all
ranks prior to the trial. Willingness of these officers to
participate in HIVIS-03 was at 61 % [14]. The results
from willingness study led to an exploratory study to
understand why 39 % would not be interested to take
part given the burden of HIV infection in a Tanzanian
context. The explorative study showed that participants
feared possible loss of close relationships if they enrolled
in an HIV vaccine trial; negative effect of the trial on the
reproductive biology; interference with pregnancy norms;
being unsure about risks such as the risks of acquiring
HIV infection; suffering physical harm and uncertainty of
the intentions of the researchers conducting the trial. Fur-
thermore, they feared for the outcome of a medical exam-
ination which was required in the trial, in that it could
reveal unknown diseases [19]. It was also deemed neces-
sary to carry out a study that would lead to an under-
standing of the motives behind a sub-group of Police
Officers who showed interest to volunteer for HIVIS-03
trial after coming to attend a session providing detailed
explanations about the purpose of phase I/II HIV vaccine
trials. Therefore, this paper describes the motives of
Police Officers who showed great interest to volunteer
in HIVIS-03 trial in Dar es Salaam, Tanzania.
Methods
Study setting
The study was conducted in Dar es Salaam, Tanzania. This
was a sub-study within a large HIV and AIDS project in
Tanzania that included studies of HIV incidence, labora-
tory reference values as well as willingness to participate
in an HIV vaccine trial leading up to phase I/II HIV
Vaccine trial among Police Officers [14, 19].
Population
The study population comprised of Police Officers from
Dar es Salaam, Tanzania. Police officers were chosen for
this study because most of them have attained four years
of secondary education, and they were easily accessible
as they come from an established organization. Deliber-
ate efforts were made to ensure that participation was
not coercive in any way.
Study design
This was a descriptive cross-sectional study based both
on quantitative and qualitative data.
Recruitment
Two hundred sixty five (265) participants were recruited
after a series of sensitization meetings and general edu-
cation sessions about HIV/AIDS and HIV vaccine trials
[14, 19]. Fig. 1 narrates the sampling procedure of the
participants. In brief, the trial implementers provided in-
formation about HIV and AIDS in detail. In addition,
the trial implementers described all issues pertaining to
HIV vaccine trials, potential benefits and risks of taking
part. Examples of benefits were: complete medical check
up for potential volunteers, and if they participate in the
trial, they would get free medical services and referral to
accredited health centres in case of illness, follow up visits
and regular HIV testing. In addition, expected vaccine in-
duced harm, such as vaccine induced seropositivity, local
pain or tenderness, local redness and various systemic
symptoms such malaise and headache, mild fever and nau-
sea were described. After the workshop, several workshop
attendees showed interest to volunteer for HIVIS-03, a
phase I/II trial. All participants (265) who showed interest
to volunteer for HIVIS-03 trial were invited for a pre-
screening workshop in groups of 40 -50 individuals. This
study was conducted during the HIVIS-03 pre-screening
workshops (Fig. 1).
Data collection
We collected data before the start of each pre-screening
workshop. The potential volunteers were asked to fill in
a questionnaire after giving consent. The questionnaire
was divided into two parts. Part one consisted of socio-
demographic data, and part two consisted of an open-
ended question requiring the potential volunteers to
narrate, in their own words, what motivated them to
volunteer for an HIV vaccine trial.
The first author (EAMT) interchangeably with the sec-
ond author (MB) asked the participants to anonymously
narrate their views. The seating plan (chair with a writing
arm) enhanced comfort ability of working individually. All
questionnaires were collected and sealed in an envelope
ready for data entry and analysis. Filling-in of question-
naires took 10-15 min. These data were collected between
June 2006 and July 2007.
Data analysis
Analysis went down in four stages
Stage I The first author carefully read all the question-
naires in the original language, Kiswahili. She converted
the handwritten text into an electronic format. A bilin-
gual research scientist (ZS) translated the Kiswahili ver-
sion into English. The two authors, EAMT and DCVK
independently read both the Kiswahili and English texts
to ensure translation consistency; minor corrections
[tenses] were made. EAMT checked the completeness
of personal characteristics in each questionnaire. A
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total of 23 respondents did not complete their socio-
demographic characteristics and were excluded from
analysis. Manifest content analysis approach was applied
during formation of categorical statements. Categorical
statements that best described what each respondent
communicated were constructed to guide the next stage
of analysis (Table 1).
Stage II To maintain integrity, EAMT and DCVK
checked the categorical statements against respondents’
original text. Minor differences were discussed and agreed
upon. Therefore, all categorical statement(s) that best de-
scribed the respondents’ motives were moved to the next
stage of analysis. A variable was formed against each cat-
egorical statement to facilitate data entry and analysis in
SPSS software.
Stage III The first author, transferred socio-demographic
characteristics and the constructed variables (Table 1) into
SPSS for windows version 20 (SPSS, Chicago, IL). The
frequency distributions and proportions of all variables
were tabulated. Descriptive statistics and cross tabula-
tions to associate the socio-demographic characteris-
tics and the selected variables were carried out. We
used Pearson Chi Square Test to test significance of
association.
Stage IV In the final presentation, analysis shifted be-
tween the categorical statements and the original texts
to select sample phrases from the respondents’ voices.
To balance gender, quotes were drawn from both men
and women.
Fig. 1 Sampling framework
Table 1 Example of socio-demographic characteristics, original text, categorical statements, and variables used for SPSS analysis
SN. Age Sex Education Marital
status
Original text Categorical Statements Variables for SPSS
217 37 Male Secondary School
(Form IV)
Married To know my health status; to protect
my body against HIV infections when
I get HIV vaccine, if I get more
information about this HIV, to educate
other community from not being
infected against HIV as an enthusiast.
-To know my health status kno_stat, get_prot
get_edu edu_othe
-To get protection against HIV
-To know more about [HIV or vaccine]
-To give education to others about HIV
[prevention or vaccine]
Tarimo et al. BMC Public Health  (2016) 16:182 Page 3 of 9
Justification of the data collection tool and analysis
process
From the onset of study design, we proposed to use an
open ended-question to assess individuals’ motivations
to take part in the HIVIS-03. The use of elements of
quantitative and qualitative analysis approaches helped
to categorize and organize descriptive data into a mean-
ingful and objective presentation.
Ethical considerations
Ethical clearance was obtained from the Institutional Re-
view Board at Muhimbili University of Health and Allied
Sciences (MUHAS). Prospective study participants pro-
vided written consent prior to their participation. Issues
of confidentiality and anonymity were strictly adhered
to. Respondents were free to respond to the question-
naire and were requested not to write their names for
the sake of anonymity. In spite of the presence of the
study team in the venue during data collection, the re-
spondents’ freedom was highly respected.
Results
Socio-demographic characteristics of the study
respondents
Of the 265, a total of 242 respondents completed the
questionnaire by providing their socio-demographic
characteristics as well as motivations to take part in the
proposed trial. The mean (SD) age was 30.7 (7.9). The
majority of respondents, 76 % (184 of 242), were males.
There was a gender difference with respect to age (Pear-
son Chi Square, P < 0.05); females were likely to be
younger than males. All socio-demographic characteris-
tics are summarized in Table 2. Approximately half of
the males were married. Majority of females were youn-
ger, not married, and were educated up to four years of
secondary education or above. It was not investigated if
they had children or not.
Motivations to participate in an HIV vaccine trial
From an open-ended question, 12 categorical state-
ments about motivations to participate in an HIV vac-
cine trial were recorded from the respondents. These
statements were presented according to the respective
socio-demographic characteristics (sex, marital status and
education level) ranging from the highest to the lowest
frequency in the quantitative section (Tables 3, 4, 5). Fur-
thermore each category will be presented with supportive




There was a statistically significant difference of reasons
to participate in the HIV vaccine trial between men and
women. Whereas women were motivated by altruism
(P < 0.01), men were motivated by researchers’ explan-
ation about HIV/AIDS vaccine studies (P < 0.001) and
intention to cooperate with researchers in developing
an HIV vaccine (P < 0.05 (Table 3).
Motivations by marital status
There was a significant difference in terms of reasons to
participate in the HIV vaccine trial between the married
and the unmarried participants. Unlike those who were
married, respondents who were unmarried were motivated
to participate by the researchers’ explanations about
HIV/AIDS vaccine studies (P < 0.05) (Table 4).
Motivations by education
There was a significant difference of motivations to par-
ticipate in the HIV vaccine trial in relation to educational
status. Compared to other levels those who attained four
years of secondary education level were more likely to
volunteer because of researchers’ explanations about
HIV/AIDS vaccine studies (P < 0.05). On the contrary
those who attained seven years of primary education as
compared to those who attained secondary education
were more likely to volunteer because of knowing their
health status (P < 0.05) (Table 5).
Qualitative Section
Volunteerism to rescue lives of others (altruism)
The majority of the respondents commonly cited altruism
as a motivation to volunteer in HIVIS-03. There was a
gender difference with respect to altruism where women
were more likely than men to volunteer on account of
altruism. They expressed their altruism as follows:
Table 2 Socio-demographic characteristics of the respondents
Responses Sex Total,
n (%)
Men, n (%) Women, n (%)
Marital status
Not married 95 (51.6) 34 (58.6) 129 (53.3)
Married 89 (48.4) 24 (41.4) 113 (46.7)
Age groups
Up to 24 36 (19.6) 23 (39.7) 59 (24.4)*
25-34 88 (47.8) 20 (34.5) 108 (44.6)
35-44 46 (25) 12 (20.7) 58 (24.0)
45+ 14 (7.6) 3 (5.2) 17 (7.0)
Education
Primary (7 years) 54 (29.3) 18 (31) 72 (29.8)
Secondary and above (4 years) 130 (70.7) 40 (69) 170 (70.2)
Significance denoted by: * = P < 0.05
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“The thing that motivates me most is to get HIV vaccine
which will be able to perish the HIV infection and save
lives of many Tanzanians … especially youths and
children” (26 years old, unmarried woman)
“I decide to volunteer in order to save lives of
Tanzanians and the world at large…”(24 years old
unmarried man)
Desire to become a role model, to be among the enthusiasts
The desire to be a role model to others through partici-
pation in HIVIS-03 was cited by several respondents.
The following statements refer to expressions of men
and women:
“I am very happy to be among the Tanzanians
participating … I will be among the people who helped
to stop this disease” (25 years old, unmarried man)
“… is to be a model or source for developing that
vaccine; without me to volunteer for vaccine trial, who
will do it..?” (32 years old, married woman)
Researchers’ explanations about HIV/AIDS vaccine studies
Fifteen percent of the participants stated that they were
motivated to volunteer in the HIVIS-03 after explanations
about the nature of the HIV and/or HIV vaccine studies
provided by researchers. Here more men than women
were motivated by researchers’ explanations. They stated:
Table 3 Motivations for participation in an HIV vaccine trial by sex
Categorical statements Men n(%) Women n(%) Total n(%)
Volunteerism to rescue lives of others [altruism] 64 (34.8) 32 (55.2) 96 (39.7)**
Desire to become a role model, to be among the enthusiasts 32 (17.4) 13 (22.4) 45 (18.6)
Researchers’ explanations about HIV/AIDS vaccine studies 36 (19.6) 1 (1.7) 37(15.3)***
To get more knowledge about HIV prevention/vaccine 27 (14.7) 10 (17.2) 37 (15.3)
To know my health status [know health status] 29 (15.8) 7 (12.1) 36 (14.9)
To get knowledge for educating others about HIV or vaccine 29 (15.8) 5 (8.6) 34 (14.0)
To cooperate with researchers in developing an HIV vaccine 21 (11.4) 2 (3.4) 23 (9.5)*
To accomplish personal motivation 14 (7.6) 5 (8.6) 19 (7.9)
To get protection against HIV infection 13 (7.1) 4 (6.9) 17 (7.0)
Magnitude of the disease [AIDS] 14 (7.6) 3 (5.2) 17 (7.0)
Severity of the disease in families – experienced death of a relative due to AIDS 13 (7.1) 2 (3.4) 15 (6.2)
Others (free treatment/insurance, test the strength of vaccine in the body) 6 (3.3) 1 (1.7) 7 (2.9)
Significance denoted by: *** = P < 0.001; ** = P < 0.01; * = P < 0.05
NB: The columns represent multiple responses, and thus cannot add up to 100 %. The same applies to the total number of respondents in each column
Table 4 Motivations for participation in an HIV vaccine trial by marital status
Categorical statements Unmarried n(%) Married n(%) Total n(%)
Volunteerism to rescue lives of others [altruism] 52 (40.3) 44 (38.9) 96 (39.7)
Desire to become a role model, to be among the enthusiasts 24 (18.6) 21(18.6) 45 (18.6)
Researchers’ explanations about HIV/AIDS vaccine studies 25 (19.4) 12 (10.6) 37 (15.3)*
To get more knowledge about HIV prevention/vaccine 19 (14.7) 18(15.9) 37 (15.3)
To know my health status [know health status] 17 (13.2) 19(16.8) 36 (14.9)
To get knowledge for educating others about HIV/vaccine 16 (12.4) 18(15.9) 34 (14.0)
To cooperate with researchers in developing an HIV vaccine 15 (11.6) 8 (7.1) 23 (9.5)
To accomplish personal motivation 10 (7.8) 9 (8.0) 19 (7.9)
To get protection against HIV infection 7 (5.4) 10 (8.8) 17 (7.0)
Magnitude of the disease [AIDS] 7 (5.4) 10 (8.8) 17 (7.0)
Severity of the disease in families – experienced death of a relative due to AIDS 8 (6.2) 7 (6.2) 15 (6.2)
Others (free treatment/insurance, test the strength of vaccine in the body) 3 (2.4) 4 (3.6) 7 (2.9)
Significance denoted by: * = P < 0.05
NB: The columns represent multiple responses, and thus cannot add up to 100 %. The same applies to the total number of respondents in each column
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“The thing that motivates me … is the education, the
adequate information I received in one of the
seminars…” (32 years old, unmarried man)
“It is after attending these seminars and understood
about this HIV vaccine…” (38 years old, married
woman)
To get more knowledge about HIV prevention/vaccine
Some respondents were motivated to volunteer in HIVIS-
03 in order to gain more knowledge about HIV/AIDS or
HIV vaccine trials. They perceived the trial as an oppor-
tunity for more information:
“I saw it is very important to join this program in
order to get more understanding on how to avoid HIV
infection” (30 years old, married man)
“Mostly is to understand, how this HIV vaccine can
help to prevent this dangerous disease…” (24 years old,
unmarried woman)
To know my health status (Know health status)
Some of the respondents were motivated to partici-
pate based on the medical check-ups which are essen-
tial prior to enrolment into the HIV vaccine trial that
will give them an opportunity to know their health
status.
“Firstly, I want to understand my health status…”
(25 years old, unmarried man)
“The thing that motivates me until reaching the
decision is to know in detail about my health status”
(26 years old, unmarried woman)
To get knowledge for educating others about HIV/vaccine
Others were motivated by the opinion that they could
get more education about HIV and or HIV vaccine trials
from the workshops and educate others:
“… if I get more information about this HIV, I will
educate other community members from not being
infected with HIV…” (37 years old, married man).
“As a parent, I will get sufficient education through
attending these seminars… to be able to educate my
family against this disease [AIDS]” (42 years old,
married woman).
To cooperate with researchers in developing an HIV vaccine
About 11.4 % of men expressed a motivation to partici-
pate in the HIV vaccine trial as being “to cooperate with
the research team in the process of developing an HIV
vaccine” The corresponding proportion among the 58
women was even fewer (3.4 %).
Below are some excerpts:
“The reason that motivates me to participate in HIV
vaccine is to cooperate with the research team …the
community cannot get out of this disaster without a
vaccine” (28 years old, married man).
“The thing that motivates me to participate in HIV
vaccine is in order to make a success on the whole
research against HIV infection…” (21 years old,
unmarried woman)
To accomplish personal motivation
Those respondents motivated by their individual motives to
participate in the HIV vaccine trial expressed as follows:
Table 5 Motivation for participation in an HIV vaccine trial by educational level
Categorical statements Primary n(%) Secondary n(%) Total n(%)
Volunteerism to rescue lives of others [altruism] 25(34.7) 71 (41.8) 96 (39.7)
Desire to become a role model, to be among the enthusiasts 24 (18.6) 21(18.6) 45 (18.6)
Researchers’ explanations about HIV/AIDS vaccine studies 4 (5.6) 33 (19.4) 37(15.3)*
To get more knowledge about HIV prevention/vaccine 10 (13.9) 27(15.9) 37 (15.3)
To know my health status [know health status] 18 (25.0) 18(10.6) 36 (14.9)*
To get knowledge for educating others about HIV/vaccine 14 (19.4) 20(11.8) 34 (14.0)
To cooperate with researchers in developing an HIV vaccine 6 (8.3) 17(10.0) 23 (9.5)
To accomplish personal motivation 8 (11.1) 11 (6.5) 19 (7.9)
To get protection against HIV infection 5 (6.9) 12 (7.1) 17 (7.0)
Magnitude of the disease [AIDS] 5 (6.9) 12 (7.1) 17 (7.0)
Severity of the disease in families– experienced death of a relative due to AIDS 3 (4.2) 12 (7.1) 15 (6.2)
Others (free treatment/insurance, test the strength of vaccine in the body) 0 (0) 7 (4.2) 7 (2.9)
Significance denoted by: * = P < 0.05
NB: The columns represent multiple responses, and thus cannot add up to 100 %. The same applies to the total number of respondents in each column
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“It is my personal motives” (38 years old, unmarried
man)
“In reality, personally, what I desire most is one day a
vaccine will be obtained” (24 years old, married
woman)
To get protection against HIV infection
Some respondents were motivated through an expect-
ation of getting personal protection against HIV infec-
tion through the trial.
“The thing that motivates me to participate in HIV
vaccine is … I have a wife, everyone has. Between us,
one can betray the other, so the vaccine will help. In
my work sometimes I face environment with injured
persons…this vaccine can help on such environment”
(27 years old, married man)
“To be among the policewomen who are provided with
protection against HIV …” (36 years old, married
woman)
Magnitude of the disease [AIDS]
Equally, a number of male and female were motivated
by the overwhelming HIV epidemic, which exists both at
national and global level:
“This disease has been a threat in our nation and the
world at large” (26 years old, unmarried man)
“The decision to participate in this HIV vaccine is that
spread of HIV calamity among human beings”
(27 years old, married woman)
Severity of the disease in families - experienced death of a
relative due to AIDS
Few respondents were motivated because of experiencing
death of a close member of the family due to AIDS. They
felt obliged to participate in the trial to prevent future
deaths:
“After seeing my three relatives died of AIDs and also
the way I understand the importance of getting HIV
vaccine in order to save lives of many people”
(49 years old, married man)
“I have lost my relatives with AIDS; so I am ready to
participate” (23 years old, unmarried woman)
Others (free treatment/insurance or test the strength of the
vaccine in the body)
A small number of the respondents were motivated by
reasons such as obtaining free medical treatment/
insurance and/or testing the strength of the vaccine in
their bodies:
“If I will be found with a problem, I will be freely
treated” (28 years old, married man)
“In order to know if the vaccine will help or not…”
(32 years old, married woman)
Therefore, the above testimonies complement the quan-
titative results and increase our understanding about
potential volunteers’ desire of taking part in HIVIS-03.
Discussion
The fact that the majority of the respondents were moti-
vated to volunteer for HIVIS-03 due to altruism is worth
noting. This implies that, many respondents were con-
cerned about the burden which HIV/AIDS has imposed
upon their lives and the society at large. This corresponds
to findings from previous studies where altruism has been
cited as a motivation for people to participate in HIV vac-
cine trials [3, 20, 21]. In the present study, increasingly
women were altruistic to volunteer than men implying
that women were more concerned about the burden of
HIV infection in their lives than men. This could be due
to the fact that studies have shown that in most cases
women share a greater burden of the HIV epidemic than
men [22]. Although some participants stick on the phrases
related to altruistic motives, they may also share experi-
ences of losing a close relative due to HIV/AIDS. For ex-
ample, death of a close relative due to AIDS can definitely
motivate one to volunteer to prevent future deaths if a
preventive effective vaccine could be developed.
The researchers’ explanations about HIV/AIDS, HIV
vaccine development and trials appeared to motivate po-
tential volunteers to participate in HIVIS-03 implying
that vaccine trial knowledge has an impact on people’s
decision to take part in vaccine trials. This motivation
was higher among men suggesting that men are more
likely to benefit from correct facts about HIV vaccines
and trials than women. Also researchers’ explanations
appear to motivate those who were unmarried and edu-
cated up to four years of secondary education or higher.
These personal characteristics can influence one to make
informed decision in participating in HIV vaccine trials.
Previous studies documented an increasing demand for
basic HIV vaccine education to address vaccine trial
concepts [4, 9, 11, 12, 14, 19]. In the current study, the
observed influence of researchers’ explanations and in-
formation in relation to gender, education and marital
status is important.
The fact that more men than women were eager to co-
operate with researchers might have been influenced by
individual understanding of the purpose of phase I/II
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HIV vaccine trials. This kind of positive intention to help
researchers in developing an HIV vaccine has been noted
elsewhere [7]. On the contrary, several studies have
shown that scientists conducting HIV vaccine trials are
mistrusted [17, 19, 23–25], and thus research participants
may display negative attitudes towards participation in
HIV vaccine trials. Nevertheless, our study shows that
HIV vaccine trial education may overcome this mistrust.
In addition, the intention of several participants wanting
to share information about HIV and vaccines with others
indicates a thirst for HIV and vaccine education in the
general community.
Taking into account that only a few respondents were
motivated to take part in the trial by expectation of get-
ting personal protection against HIV infection implies
that potential volunteers understood that they could not
expect to get protection against HIV from an experimental
vaccine phase I/II trial. A previous study from the same
population [14] indicated that participants were expecting
to get protection against HIV by participating in an HIV
vaccine trial; however, that study was done before detailed
educational workshops. Similarly, elsewhere studies re-
vealed that study participants were motivated to volunteer
for HIV vaccine trials for personal protection against HIV
infection [12, 16, 20, 26]. However, some of those studies
were conducted before HIV vaccine trial education. It is
also worth noting that increasingly the demand to know
more about HIV prevention and vaccines indicate the
need of provision of education specific for HIV and HIV
vaccines prior to implementation of HIV vaccine trials.
Methodological considerations
The present study was conducted in a non-random sam-
ple, which makes generalization of the results difficult.
We avoided a standardized questionnaire so as not to
pre-empt the individuals’ motives. Therefore, we used a
questionnaire with open-ended questions to examine the
diversity of motivations for participation in an HIV vac-
cine trial among police officers. This approach demands
high level of flexibility in data analysis than would be the
case if closed ended questions were used. To avoid dis-
crepancies in interpreting the results, more than one
researcher analysed the data. Negotiation for the right
meaning of the respondents’ expressions was done to
agree on correct categorical statement(s) to use. The
prior relationship between the researchers and the re-
spondents could influence the results. To decrease this
social desirability, anonymity was emphasised during
data collection. On the contrary, the incomplete socio-
demographic information of the 23 respondents might
have been influenced by adherence to anonymity. Never-
theless most of the respondents completed the required
socio-demographic information.
Conclusions
The results show that volunteers in HIV vaccine trials
are likely to be motivated by multiple reasons. Altruism
as cited by the majority may be the main motivation in
an African setting where the burden of HIV is deeply ex-
perienced. Educational sessions prior to HIV vaccine tri-
als are revealed to be crucial to increase understanding
about the conduct of these trials especially in settings
where HIV vaccine trials are perceived as new concepts.
Therefore, participation in an HIV vaccine trial in a
Tanzanian context is more likely to be influenced by al-
truism and comprehensive education about the trial. In
addition, to enhance recruitment in future trials, gender
differences, marital status and education level should
be taken into consideration. Unrealistic motivation such
as getting protection from an experimental vaccine albeit
mentioned by few respondents should be taken into
consideration during recruitment processes. Thus, the
knowledge gained from this study can better inform
trial implementers to consider context specific motiva-
tions during recruitment of volunteers into HIV vaccine
trials.
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